Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.

ABSTRACT: The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway regulates proliferation, survival and metabolism, and its dysregulation is one of the most frequent oncogenic events across human malignancies. Over the last two decades, there has been significant focus on the clinical development of PI3K pathway inhibitors. More than 40 different inhibitors of this axis have reached various stages of clinical trials, but only a few of them have been approved by the Food and Drug Administration (FDA) for cancer treatment. These clinical results, however, could be improved given the importance of PI3K signaling in cancer and its role in linking cancer growth with metabolism. In this systematic review, after a glance at PI3K/AKT/mTOR pathway and its different inh

SUBMITTER: Davoodi-Moghaddam Z 

PROVIDER: S-EPMC11796912 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature